Zitong Financial App News$Sihuan Medicine (00460.HK) $It is announced that the proposed final cash dividend of RMB1.3 per share for 2021 and the proposed special cash dividend of RMB9.5 per share have been approved by shareholders at the annual general meeting. Final cash dividends and special cash dividends payable to shareholders will be converted into Hong Kong dollars and paid in Hong Kong dollars. The final cash dividend and special cash dividend payable in Hong Kong dollars are HK $1.6 per share and HK $11.7 per share respectively.
四环医药(00460)将派2021年度末期现金股息每股1.3分及特别现金股息每股9.5分
Sihuan Pharmaceutical (00460) will pay a final cash dividend of 1.3 cents per share and a special cash dividend of 9.5 cents per share.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.